Hl60 cells atcc ccl 240

The three cell lines used were all cultured in conformity with the sterile technique and the standard mammalian cell culture protocols under a 5% CO₂ atmosphere at 37 °C.
Lymphocyte cell line (IST-EBV-TW6B) was purchased from the cell bank IRCCS AOU San Martino IST (Italy). Cells were cultured in advanced RPMI 1640 culture medium (Gibco) with 20% of heat inactivated fetal bovine serum (FBS, Gibco), 1% penicillin/streptomycin (P/S, Sigma) and 1% of l-Glutamine 200 mM (Lonza) in 75 cm² not treated cell culture flasks (Corning) maintaining the cell density between 9 × 10^4–5 cells/mL.
Daudi cells (ATCC® CCL­213™), originating from a Burkitt’s lymphoma patient, were obtained from American Type Culture Collection (ATCC). Cells were grown in RPMI 1640 culture medium (ATCC) supplemented with 10% of heat inactivated FBS (ATCC), 1% P/S (Sigma) in 75 cm² not treated cell culture flasks (Corning) with a cell density between 3 × 10^5–6 cells/mL.
HL60 cells (ATCC® CCL-240™), from an acute myeloid leukemia patient, were purchased from ATCC. They were maintained in Iscove’s Modified Dulbecco’s Medium (Sigma) with 20% heat inactivated FBS (Sigma), 1% Glutamine (Sigma), 1% P/S (Sigma) in 75 cm² not treated cell culture flasks (Corning), adjusting cell density to 1 × 10^5–6 cells/mL.

All cell lines were cultured according to standard mammalian cell culture protocols and a sterile technique at 37 °C under a 5% CO₂ atmosphere.
Daudi cells (ATCC^® CCL-213™), derived from a patient affected by Burkitt’s lymphoma, were obtained from American Type Culture Collection (ATCC). Cells were cultured in RPMI 1640 culture medium (ATCC) supplemented with 10% of heat-inactivated fetal bovine serum (FBS, ATCC), 1% penicillin/streptomycin (P/S, Sigma) in 75 cm² non-treated cell culture flasks (Corning). The cell density was maintained of 3 × 10^5–6 cells/mL.
The lymphocyte cell line (IST-EBV-TW6B) was purchased from the cell bank IRCCS AOU San Martino IST (Italy). Cells were grown in advanced RPMI 1640 culture medium (Gibco) with 20% heat-inactivated FBS (Gibco), 1% L-glutamine 200 mM (Lonza), and 1% P/S (Sigma) in 75 cm² non-treated cell culture flasks (Corning) with a cell density of 9 × 10^4–5 cells/mL.
HL60 cells (ATCC^® CCL-240™), derived from an acute myeloid leukemia patient, were obtained from ATCC. They were maintained in Iscove’s Modified Dulbecco’s Medium (Sigma) with 20% heat-inactivated FBS (Sigma), 1% glutamine (Sigma), 1% P/S (Sigma) in 75 cm² non-treated cell culture flasks (Corning), adjusting the cell density to 1 × 10⁵⁻⁶ cells/mL.

K562 (ATCC CCL-243) and HL-60 cells (ATCC CCL-240) (American Type Culture Collection, Manassas, VA, USA) were cultured, mixed and lyophilized following methods described by White et al.^{14 (link)} with minor modifications (Supplementary Information). Calibration to the WHO standards was performed as described.^{14 (link)} IS calibration using ABL1 as a reference gene was conducted using 10 sets of WHO ‘first International Genetic Reference Panel for quantitation of BCR-ABL mRNA' panels (National Institute for Biological Standards and Control, South Mimms, UK). Calibration using BCR and GUSB was conducted in a second study using another 10 sets of WHO panels. On each day of 10 non-consecutive days, 1 WHO panel and 2–3 secondary panels were tested using RT-ddPCR in 4 replicates for the MR¹ (10% BCR-ABL^IS) to MR⁴ (0.01% BCR-ABL^IS) samples and in 8 replicates for the MR^4.5 (0.0032% BCR-ABL^IS) sample, to enhance assay precision. Data analysis was performed using the statistical methods described by White et al.^{14 (link)}